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1. Introduction 
The misuse of mephedrone (4-methylmethcathinone) has been increasing greatly in Western 
countries over the last two years or so, especially in the club and dance scenes. This period 
has also been marked by claims that the substance has been implicated in a rising number of 
deaths in the USA and Western Europe, especially the United Kingdom (UK).  
This chapter explores the context(s) and evolution of mephedrone use in the UK, and the 
circumstances in which these fatalities occurred. Particular attention is paid to the settings in 
which these incidents took place, their symptomatology and physical characteristics; 
intervention/treatment opportunities; and toxicological and pathological findings. These 
results are related to the known pharmacological facts regarding mephedrone, its possible 
interactions with alcohol and other psychoactive drugs, and suggested clinical interventions 
and treatment(s).  
The relationship between mephedrone, other methcathinones, and other emerging novel 
psychoactive substances, as well as established stimulants is also examined. These 
developments are important as novel substances used for recreational use become more 
globally accessible through the use of the Internet. 
2. Recreational use 
Mephedrone (4-methylmethcathinone;  ‘Plant Food’, ‘Meow Meow’, ‘Miaow’, ‘Drone’, 
‘Meph’, ‘Bubbles’, ‘Spice E’, ‘Charge’, ‘M-Cat’, ‘Rush’, ‘Ronzio’, ‘Fiskrens’ and ‘MMC 
Hammer’) ( Schifano et al, 2011) is the most popular of the cathinone derivatives, which also 
include butylone, flephedrone, MDPV, methedrone, methylone, pentylone, and other 
compounds (ACMD, 2010; Morris, 2010). It has been readily available for purchase both 
online and in head shops as a ‘legal high’, and more recently as a ‘research chemical’; its 
circulation has been promoted by aggressive web-based marketing (Deluca et al., 2009). 
Mephedrone elicits stimulant and empathogenic effects similar to amphetamine, 
methylamphetamine, cocaine and MDMA (Winstock et al., 2010). However, as we write, 
relatively few formal related papers and experimental/clinical data have been published 
(Dargan et al., 2010; Winstock et al., 2010; Winstock et al., 2011).  
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The synthesis of mephedrone was first described over 80 years ago (Saem de Burnaga 
Sanchez, 1929). However, the first Internet reference to it occurred reportedly in May 2003 
(Power, 2009), but both its availability for purchase online (Camilleri et al., 2010; Roussel et 
al., 2009) and its related popularity only started in 2007 (Deluca et al., 2009). Data collected 
by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) indicate that 
during the first quarter of 2010, there were detections in some 20 EU Member States, with 
most of them reporting small- to medium-sized seizures (Europol-EMCDDA, 2010). During 
the second quarter of 2009, the UK Forensic Science Service received submissions of three 
times as many samples of mephedrone for analysis than it had in the previous 12-month 
period (ACMD, 2010; Ghodse et al., 2010). Since mephedrone appeared comparatively 
recently on the market, it does not feature in most drug use household surveys, and it is 
uncertain how many people present with a history of mephedrone misuse. Most available 
data originate from self-reported surveys and small focus group research.  
The main settings for mephedrone use appear to be nightclubs, parties and people’s homes 
(Newcombe, 2009). A survey of readers of the dance magazine ‘Mixmag’ found that 41.7% 
of respondents had ever tried mephedrone and 33.2% had used it during the previous 
month (Winstock et al., 2011). Dargan et al. (2010) assessed both the prevalence and 
frequency of use of mephedrone by students in Tayside (Scotland) in February 2010. Some 
20.3% reported previous use of mephedrone; 23.4% reported using only using mephedrone 
on one occasion previously and 4.4% reported daily use. A total of 48.8% of users had 
sourced mephedrone from street-level dealers and 10.7% from the Internet. Heightened 
awareness and interest in mephedrone was reflected by a rise in the number of both 
telephone inquiries and visits to both the TOXBASE and FRANK web sites (ACMD, 2010; 
James et al., 2010). The 2011 sweep of the British Crime Survey, which covers households in 
England and Wales, found that 4.4% of adults aged 16 to 24 years had used mephedrone in 
the last year, compared to only 0.6% of those aged 25 to 59 years (Smith & Flatley, 2011). The 
rate for the younger age-group is similar to that for cocaine. The majority of respondents 
who had taken mephedrone in the last year had also taken another drug. It is, therefore, 
likely that it is existing users of drugs that are taking mephedrone rather than new users 
drawn to drug taking. 
The emergence of mephedrone on the UK recreational drug scene may be linked to 
decreasing purity in the UK of both MDMA (ecstasy) and cocaine (Mulchandani et al., 2010; 
Fleming, 2010; Measham et al., 2010; NTA, 2010). As a consequence, drug users may have 
switched to mephedrone, as it was seen as cheaper and more powerful than the currently 
available ‘traditional’ stimulants (Deluca et al., 2009). Its availability over the Internet and its 
status as a ‘legal high’ (and therefore presumed not to be harmful) may have boosted its 
appeal (Daly, 2010; Ramsey et al., 2010).  
3. Legal status 
Mephedrone is not scheduled under the 1971 United Nations Convention on Psychotropic 
Substances. In Australia, New Zealand, and the USA mephedrone is considered as an 
analogue of other illegal substances already  and can be controlled by laws similar to the 
Federal Analog Act. In March 2010, the EMCDDA and Europol submitted a joint report on 
mephedrone to the Council of the European Union, the European Commission and the 
European Medicines Agency (EMA), presenting the case for a formal risk assessment of the 
 
Mephedrone-Related Fatalities in the United Kingdom: Contextual, Clinical and Practical Issues 
 
357 
drug  (Europol-EMCDDA, 2010). The risk assessment report, which was submitted to the 
European Commission and the Council of the European Union on 26 May 2010, examined 
the health and social risks of the drug, as well as information on international trafficking 
and the involvement of organised crime. Furthermore, the report considers the potential 
implications for placing the drug under control in the EU. On the basis of this report — and 
on the initiative of the European Commission — on 2 December 2010, the Council decided 
that mephedrone is to be subject to control measures (EMCDDA, 2011).  
In the UK, where mephedrone had been attracting great attention from both the mass media 
and the Government, the Advisory Council on the Misuse of Drugs (ACMD) submitted a 
report to the Home Office on the cathinone derivatives, recommending their inclusion in the 
Misuse of Drugs Act 1971 as a Class B drug (ACMD, 2010). The Home Office announced on 
30 March 2010 that this recommendation would be enforced from 16 April 2010 (Home 
Office, 2010). 
4. Chemistry  
Mephedrone is a semi-synthetic compound belonging to the chemical class of cathinone 
derivatives (or substituted cathinones). Cathinone is a natural amphetamine-like alkaloid 
found in the fresh leaves and stems of the African shrub Khat (Catha edulis) (Kalix, 1992). 
The systematic name of mephedrone is 2-(methylamino)-1-(p-tolyl)propan-1-one(2S)-2-
(methylamino)-1-(4-methylphenyl)propan-1-one, in accordance with the International 
Union of Pure and Applied Chemistry. The structure of mephedrone differs from cathinone 
by methylation of the amino group and the benzene ring present (Gustaffsson and Escher, 
2009; Osorio-Olivares et al., 2003). The cathinones are beta-keto derivatives of 
phenethylamines, and hence analogues of amphetamines (Chemspider, 2010). Since they are 
mainly synthetic in origin, beta-keto amphetamines are also known as ‘bk designer drugs’. It 
is relatively easy to produce mephedrone in nonprofessional laboratories via bromination of 
4-methylpropiophenone followed by reaction with methylamine or by oxidation of 4-
methylephedrine (Archer, 2009; Europol-EMCDDA, 2010).  
Although mainly sold in powder and crystal forms, mephedrone may be commercially 
available in tablets and included within vegetable-based capsules. It has been reported 
that mephedrone is sometimes sold in some countries as either ecstasy or ‘synthetic’ 
cocaine (Deluca et al., 2009; Schifano et al., 2011). Furthermore, it may be found mixed 
with adulterants, such as caffeine, paracetamol and even cocaine, amphetamine and 
ketamine (Camilleri et al., 2010), as well as with other methcathinones (as revealed by 
information supplied to the National Programme on Substance Abuse Deaths by coroners 
– see below). 
5. Pharmacology 
Given the affiliation of cathinone derivatives to beta-keto amphetamines, mephedrone 
would be expected to act as a Central Nervous System stimulant. In vitro studies on the 
effects of the cathinone derivatives methcathinone and methylone confirm that the main 
mechanism of action is very similar to that of amphetamine, being characterised by a 
predominant action on plasma membrane catecholamine transporters (Cozzi et al., 1999). 
The presence of the ring substituent on the phenethylamine core modifies the 
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pharmacological properties by giving the compound some MDMA-like effects (Europol-
EMCDDA, 2010). Cathinones’ potencies are mostly lower than those of amphetamines as 
beta-keto amphetamines show a reduced ability to cross the blood–brain barrier due to the 
presence of the beta group (Nagai et al., 2007; Gygi et al., 1996). 
N-demethylation to the primary amine, reduction of the keto moiety to the respective 
alcohol, and oxidation of the tolyl moiety to the corresponding alcohols and carboxylic acid 
is the major metabolic pathway for mephedrone, followed by N-dealkylation.  
6. Routes of administration, dosage, use in combination with other drugs, 
effects 
The most common routes for recreational use include insufflation (snorting) and oral 
ingestion. Because of its solubility in water, mephedrone is reportedly used by rectal 
administration or injected intravenously. Other typical methods of intake include oral 
ingestion as capsules or tablets; swallowing mephedrone powder wrapped up in cigarette 
paper (bombing); or mixed with water.  Insufflation is likely to be the most common 
modality as, when snorted, mephedrone elicits its effects within a few minutes, with the 
peak being reached in less than 30 min followed by a rapid comedown. According to online 
users, the mephedrone dosage for snorting may range between 25 and 75 mg, with a lower 
threshold at 5–15 mg and levels in excess of 90 mg considered a high dosage (Sumnall and 
Wooding, 2009). Dosing is more frequent when taken intranasally; this route is allegedly 
associated with greater abuse liability than the oral route (Winstock et al., 2010, 2011). On 
average, the most common oral dosages are higher than the snorting ones (Sumnall & 
Wooding, 2009), in the range 150 to 250 mg.  
Time of onset may be from 45 min to 2 h and may vary in association with the amount of 
food in the stomach. Because of this, users suggest taking mephedrone on an empty 
stomach. Psychoactive effects may last longer (up to 2–4 h) with oral ingestion; side-effects 
might be milder and the need to re-dose less urgent. Some users employ both insufflation 
and oral ingestion in combination to obtain faster onset and long-lasting effects (Deluca et 
al., 2009). Users report that rectal administration is characterised by faster onset of the effects 
and requires lower doses, e.g. 100 mg on average than oral ingestion (Deluca et al., 2009). 
Although not typically advised, because this may increase the drug’s addictive liability 
levels (Deluca et al., 2009), mephedrone may also be injected either intramuscularly (Wood 
et al., 2010a) or intravenously, at one half or two-thirds of the oral dose (Deluca et al., 2009). 
According to online user fora, mephedrone may be taken in combination with a number of 
stimulants, sedatives and psychedelics (Deluca et al., 2009; Schifano et al., 2011).  
As mephedrone has the capacity to induce tolerance on repeated dosing, an increasing 
number of user reports have stated a quick progression to either regular drug use and/or 
uncontrolled bingeing behaviour (known as ‘fiending’), with 1–4 g of mephedrone 
consumed in a session to prolong the duration of its effects (Deluca et al., 2009; Europol-
EMCDDA, 2010; Dargan et al., 2010). A recent survey carried out by a drug-related web site 
has unveiled an average monthly use of 11.16 g for each mephedrone consumer (Drugs-
forum, 2010). Although withdrawal symptoms are not commonly reported, users often 
display strong cravings for mephedrone (Newcombe, 2009). 
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The effects of mephedrone have been compared by users variously to those of cocaine, 
amphetamine and MDMA. Self-reported subjective effects may include (Winstock et al., 
2011; Deluca et al., 2009): intense stimulation and alertness, euphoria; empathy/feelings of 
closeness, sociability and talkativeness; intensification of sensory experiences; moderate 
sexual arousal; and perceptual distortions (reported with higher dosages only). 
7. Adverse effects  
Dargan et al. (2010) report that some 56% of those who had used mephedrone may complain 
of at least one unwanted effect associated with mephedrone use. These may include 
(ACMD, 2010; Deluca et al., 2009; James et al., 2010; Wood et al., 2009, 2010b): loss of 
appetite, nausea, vomiting and stomach discomfort; tremors, headache (very common), 
dizziness/light-headedness, seizures, nystagmus, pupil dilation, blurred vision, numbness 
of tactile sensitivity (reported at higher dosages); anxiety, confusion, dysphoria, aggression, 
depression, long-lasting hallucinations, paranoid delusions, short-term psychosis, short-
term mania, insomnia and nightmares, impaired short-term memory, poor concentration, 
tachycardia, elevated blood pressure, respiratory difficulties, chest pain. Possibly due to 
vasoconstriction, users have anecdotally described cold/blue fingers. Of particular interest 
are recent reports of clinical significance: severe refractory left ventricular failure (Chhabra 
et al., 2010); and acute myocarditis (Nicholson et al., 2010). Further unwanted effects may 
include: difficulties in urination, possible nephrotoxicity, anorgasmia; changes in body 
temperature regulation, with hot flushes and sweating; immunological toxicity (vasculitis, 
infections and ulcerations); posterior reversible encephalopathy syndrome (Omer & 
Doherty, 2010); and finally serotonin syndrome (Garrett & Sweeney, 2011). 
Most of the above untoward effects seem to be similar to those already documented for 
amphetamine, methylamphetamine and MDMA (Schifano et al., 2010), implicitly 
supporting a sympathomimetic activity of mephedrone. Conversely, symptoms of 
depression and anhedonia could be tentatively associated to a putative depletion of 
serotonin and dopamine as a consequence of drug use (ACMD, 2010), similarly to what may 
occur with other stimulants (Schifano, 1996). It is impossible to determine a ‘safe’ dose for 
mephedrone since negative side-effects may present in association with any dosage taken. 
Furthermore, similar dosages may have dramatically different consequences in different 
individuals (Dickson et al., 2010). 
8. Fatalities  
During the last few months of 2009 and the first few months of 2010, the UK media were 
constantly reporting fatalities allegedly related to mephedrone consumption, but only a 
proportion of them had by that time been formally confirmed. A report on a mephedrone-
related fatality first appeared in Sweden, referring to an 18-year-old female death which 
occurred in December 2008. No other drugs, apart from mephedrone, were identified by the 
toxicological screenings (Gustaffson & Escher, 2009). Previously, a Danish teenager found in 
possession of mephedrone died in May 2008, although toxicology reports were inconclusive 
(Campbell, 2009). The first mephedrone-related death in the USA involved the combined 
use of mephedrone and heroin (Dickson et al., 2010). More recently, the first cases from the 
Netherlands (Lusthof et al., 2011) and the Republic of Ireland (EMCDDA, 2011:85) have 
been reported. 
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Given the potentially large numbers of consumers involved in the use of mephedrone across 
both the EU and the UK (EMCDDA, 2011), the main aims of this study were to report and 
analyse information relating to the socio-demographics and clinical circumstances of all 
recorded mepherone-related deaths for the whole of the UK, both when the index drug was 
taken on its own and when in combination with other drugs. The rationale for doing this is 
to make accessible a corpus of material which will help inform treatments and interventions 
so as to reduce deaths associated with the use of this drug and other methcathinones. 
9. Methodology for identifying potential mephedrone-related fatalities 
In the UK and Islands all sudden, unexpected or violent deaths - as well as deaths in 
custody - are formally investigated by Coroners (or their equivalent in the Islands), or 
Procurators Fiscal in the case of Scotland. Most drug-related deaths are subject to these 
processes, typically by way of a coronial inquest (Corkery, 2002).   
Since its establishment in 1997, the National Programme on Substance Abuse Deaths (np-
SAD) has been regularly receiving coroners' information on drug-related deaths amongst 
both addicts and non-addicts in the UK, the Channel Islands and the Isle of Man. The 
average annual response rate from coroners in England and Wales to np-SAD has been 
between 89% and 95% (Ghodse et al., 2010). Since 2004, information has also been received 
from the Scottish Crime &Drug Enforcement Agency and the General Register Office for 
Northern Ireland. To date, details of some 25,000 deaths have been received. The 
information reported here on deaths associated with mephedrone consumption are based 
on all relevant cases recorded in the Special Mortality Register of the np-SAD based at St 
George’s Hospital Medical School, University of London.  
To be recorded in the np-SAD database as a drug-related death, at least one of the following 
criteria must be met: (a) presence of one or more psychoactive substances directly 
implicated in death; (b) history of dependence or abuse of drugs; and (c) presence of 
controlled drugs at post-mortem. Full details of the np-SAD data collection form and its 
surveillance work can be found in the Programme’s annual report (Ghodse et al., 2010). 
Ethical approval is not required in the UK for studies whose subjects are deceased. 
However, confidentiality arrangements are in place with each of the respective data 
providers. 
A range of documents are contained in coronial inquest files, although the variety differs 
from case to case. Typically, the coroner has access to: statements from witnesses, family and 
friends; General Practitioner records (if the deceased is registered with one); reports from 
ambulance, police or other emergency services; hospital Emergency Department and clinical 
ward reports; psychiatric and substance abuse team reports; as well as post mortem and 
toxicology reports. Internet searches of toxicological as well as newspaper and other media 
websites revealed information on further cases. The media reports available for some cases 
were used to supplement the information provided on the np-SAD data collection form, 
especially where access to the full coronial files was not possible.  
In addition to its routine surveillance activities, the Programme also provides real-time 
information on the emergence of novel substances or new ways of taking existing 
substances to the UK Early Warning System and the Advisory Council on the Misuse of 
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Drugs (ACMD). This information comes both from notifications of deaths and from ‘alerts’ 
or other information provided by the various agencies and networks, national and 
international, with which the Programme maintains contacts. Regular searches of media 
reports are also undertaken. 
Through these channels (including coroners, forensic toxicologists – principally the London 
Toxicology Group, Drug & Alcohol Action Teams, and the Scottish Crime  & Drug 
Enforcement Agency) the Programme became aware of the emerging issue of the use of 
methcathinones, especially mephedrone, and similar substances (including chemicals), and 
of their potential adverse health consequences. It was decided to take a pro-active approach 
to monitor the situation especially in respect of the potential role of these new substances in 
causing or contributing to death. For those cases not formally reported to the Programme, 
contact was made with the relevant coroners to request the submission of an np-SD form so 
as to obtain the appropriate information. Information on these cases was added to the 
database when forms were received by the Programme team.  
The np-SAD database was searched using the terms 'mephedrone' and ‘4-
methylmethcathinone’ to identify potentially relevant cases. The database fields searched 
were those holding data on: drugs present at post-mortem; drugs implicated; cause(s) of 
death; accident details; and 'other relevant information'. The data presented here relate to all 
concluded cases for which forms had been submitted to the Programme by 31 August 2011. 
Details of some of these cases have previously been published (Torrance & Cooper, 2010; 
Wood et al., 2010b; Maskell et al., 2011; EMCDDA, 2011:78-85). 
Analyses were performed using IBM® SPSS® Statistics, version 18 for Windows™. 
Demographic details, risk factors, and categorical data were expressed as frequencies and 
percentages within groups; ages were compared using Levene’s Test for Equality of 
Variances (two-tailed). The results for statistical tests were regarded as significant at or 
below the 5% probability level.  
10. Results 
A total of 125 alleged or suspected mephedrone-associated fatalities have been identified by 
the np-SAD team (Fig. 1). However, in 25 cases (20.0%) mephedrone was not found at post 
mortem and for 13 cases (10.4%) the toxicology results are still pending. For those 87 cases 
(69.6%) where mephedrone was identified at post mortem, inquests have been concluded in 
60 cases. These were considered as confirmed fatalities meeting the above inclusion criteria, 
and on which the present analysis will focus.  
10.1 Demographics 
The mean age of the sample was 28.7 years (SD 11.3), range 14-64 years old. The mean age 
for males was 28.9 years compared to 28.0 years for females; this difference was not 
statistically significant (t = 0.27 (two-tailed for equality of means) p = 0.79 (95% CI = -5.87 to 
+7.72). Where known, most victims were described as 'White' (Table 1). Where place of birth 
was given, 39 were born in the UK and Islands and 8 overseas. Many were in employment 
(n = 25), but one-quarter (n = 16) were unemployed, and 11 were students.  
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Fig. 1. Flow-chart of UK deaths associated with mephedrone 
 
Demographic 
variable 
Characteristics 
Age (years): 
male (n=45) 
 
female (n=15) 
 
all (n=60) 
 
mean = 28.9, median = 24.9, minimum = 17.1, maximum = 63.8, range 
= 46.8, SD = 11.1. 
mean = 28.0, median = 24.9, minimum = 14.8, maximum = 55.1, range 
= 40.3, SD = 12.2. 
mean = 28.7, median = 24.9, minimum = 14.8, maximum = 63.8, range 
= 49.0, SD = 11.3. 
Age-group (years) < 15 = 1; 15-24 = 30; 25-34 = 16; 35-44 = 6; 45-54 = 5; 55-64 = 2; >64 = 0. 
Ethnicity White = 50; Black = 0; Asian = 1; Other (Filipina) = 1; Not known = 8. 
Country of birth England = 32, Wales = 2, Scotland = 1, Northern Ireland = 2, Guernsey 
= 2; overseas = 8; unknown/unavailable = 13. 
Employment status non-manual = 9; manual = 14; unemployed = 16; self-employed = 2; 
invalidity/sickness = 1; student = 11; housewife = 0; unknown = 7. 
Living 
arrangements 
alone = 11; with parents = 20; with partner = 14; with partner and 
children = 2; with friends = 4; no fixed abode = 2; self & children = 1; 
Other = 1; unknown = 5. 
Addict status non-addict = 10; addict/drug abuser = 27; unknown = 23. 
Table 1. Socio-demographics of 60 UK deaths associated with mephedrone reported to np-
SAD 
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Just over half (33) died in their home or that of a friend and 12 in hospital (Table 2). The 
verdict/conclusion returned by the coroners or procurators fiscal in 35 instances was 
accidental death or misadventure; (non-dependent) abuse of drugs in 5 cases, suicide in 10 
cases, homicide in one case, natural causes in one case, and an open verdict in 8 cases. Forty-
four of these deaths occurred in England; nine in Scotland, four in Northern Ireland, two on 
Guernsey, and one in Wales. 
Twenty-seven were known to be as 'addicts' (either dependent on or misusing drugs), and 
10 were not addicts; for 23 cases the information was not known. Only 11 of the deceased 
were known to have been prescribed psychoactive drugs: these included diazepam, 
antidepressants, antipsychotics, antiepileptics, methadone, and opioid analgesics, often in 
combination. 
Demographic 
variable 
Characteristics 
Place of death at home = 28; friend's home = 5; hospital = 12; open 
space/woodland/river = 7; other = 7; unknown = 1. 
Country of death England = 44; Wales = 1; Scotland = 9; Northern Ireland = 4; 
Guernsey = 2; Jersey = 0; Isle of Man = 0. 
Day of week of death 
(this is not 
necessarily day of 
consumption) 
Sunday = 13; Monday = 12; Tuesday = 10; Wednesday = 8; Thursday 
= 2; Friday = 5; Saturday = 10. 
Month of death Sep 2009 = 1; Oct 2009 = 1; Nov 2009 = 1; Dec 2009 = 5; Jan 2010 = 7; 
Feb 2010 = 7; Mar 2010 = 9; Apr 2010 = 6; May 2010 = 3; Jun 2010 = 1; 
Jul 2010 = 7; Aug 2010 = 2; Sep 2010 = 0; Oct 2010 = 2; Nov 2010 = 2; 
Dec 2010 = 0; Jan 2011 = 0; Feb 2011 = 2; Mar 2011 = 0; Apr 2011 = 2; 
May 2011 = 2; Jun 2011 = 0; Jul 2011 = 0; Aug 2011 = 0. 
Verdict (legal 
conclusion) 
accident/misadventure = 35; (non-dependent) abuse of drugs = 5; 
open/undetermined = 8; suicide = 10; killed unlawfully = 1; other = 
1. 
Manner of death 
(intentionality) 
natural = 1; accidental = 41; suicidal = 11; homicidal = 1; 
undetermined = 6. 
Table 2. Circumstances of 60 deaths associated with mephedrone reported to np-SAD 
The first known death in the UK occurred in September 2009. The number steadily rose to 7 
both in January and February 2010, peaked at 9 in March, falling to 6 in April, and declining 
in the next couple of months to one in June.  However, there was a further peak of 7 cases in 
July, followed by two deaths in August and another 2 in both October and November. There 
then followed a period of a few months without any reported fatalities, but the most recent 
deaths occurred in April and May 2011 (Fig. 2). There were twice as many deaths on 
Saturdays, Sundays, Mondays and Tuesdays (n = 45, average 11.2 per day) compared to the 
other days of the week (n = 15; average of 5.0 per day). It should be noted that the day of 
death was not necessarily the day that mephedrone was consumed, as in a few cases death 
occurred several days later in hospital – in one case three weeks after the event.   
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Fig. 2. Evolution of suspected deaths (n = 125) and cases with confirmed positive toxicology 
for mephedrone submitted to np-SAD as at 31 August 2011 (n = 60) 
10.2 Events leading to death 
As might be expected given the typical purpose of using mephedrone to experience its 
psychoactive effects, many deaths occurred following recreational consumption of the drug 
(Table 3), often in the deceased’s or another’s home. However, some deaths (road traffic 
collisions, drowning, hypothermia, etc.) occurred as the result of accidents through 
impaired judgement due to mephedrone use. In two cases, the deceased had been engaged 
in sexual activity.  
There was a significant number (n = 18) of deaths involving violent means, and especially 
hanging (13 cases). In several of these cases, mephedrone was considered by the 
pathologist/coroner/Procurator Fiscal to have played a role although it was not being 
specifically mentioned in the cause of death field. Mephedrone withdrawal was considered 
a contributory factor in one suicide by hanging. There were also three fatal road traffic 
accidents following consumption of mephedrone (and other drugs), and one homicide when 
the deceased was killed for his supply of mephedrone (about 500 g).  
10.3 Cause(s) of death 
The effects (‘adverse’, poisoning, intoxication, toxicity) of mephedrone, including other 
substances, were recorded in the cause of death for 24 cases (Table 4). Consumption of 
mephedrone led to a seizure in one case, and cardiac arrest in another. In a further case, 
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cardiac arrest was caused by multiple drug toxicity (including mephedrone) and/or excited 
delirium. In two cases the ingestion of mephedrone with other drugs led to hypoxic brain 
injury (one with cerebral oedema). Health issues were present in a number of cases. These, 
along with mephedrone (and other substances) contributed to death; for example, 
cardiovascular conditions - 4, bronchopneumonia - 3.  
Found unresponsive/dead after taking mephedrone (and other substance) – 14 
Found hanging after paranoiac/suicidal behaviour - 6 
Found hanging following depression relationship broke up – 1 
Found hanging following row with girlfriend over his drug misuse - 1 
Self-suspension when intoxicated with alcohol and cocaine – 1 
Found hanging after no apparent untoward behaviour – 1 
Found dead after cutting own throat – 1 
Suicide by gun-shot following consumption of mephedrone, other methcathinone(s) and 
cocaine – 1 
Had consumed mephedrone and other substances, jumped from bridge where relative had 
previously committed suicide – 1 
Committed suicide by drug overdose, including mephedrone – 2 
Following family argument, took fatal levels of amitriptyline and methadone, consumed 
mephedrone – 1 
Reported missing after argument with partner, found dead next day on running track with 
suicide note, had consumed prescribed medications and mephedrone - 1  
Had taken mephedrone, but was stabbed and his large supply of mephedrone was stolen, 
bled to death – 1 
Took drugs (including mephedrone and cocaine), started behaving bizarrely, aggressively 
and abusively; police tried unsuccessfully to calm him down and had to arrest him; 
collapsed whilst under restraint and suffered cardiac arrest - 1  
Attended party, collapsed with cardiac arrest, died in hospital – 1 
Attended party, collapsed with breathing difficulties, died in hospital – 1 
Attended party, took mephedrone ‘bomb’, collapsed with very high temperature which 
prevented blood from clotting, causing abdominal haemorrhages, never regained 
consciousness - 1 
Took mephedrone and other substances, collapsed with chest pains – 2 
Took mephedrone and other methcathinones, together with cocaine, which caused fatal 
heart attack – 1 
Took cocaine and mephedrone at party, collapsed and died following day - 1 
Had consumed mephedrone but died from heroin and alcohol toxicity – 1 
Found dead after consuming Datura, dihydrocodeine, alcohol and mephedrone - 1 
Had consumed mephedrone and other stimulants, attempted to swim across river but 
drowned - 1 
Had taken mephedrone and other drugs, driving vehicle involved in fatal road traffic 
accident – 3 
Following consumption of alcohol and mephedrone, felt sick, collapsed, died in hospital – 1 
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Took alcohol and mephedrone, collapsed and unrouseable, died in hospital - 1 
Collapsed after taking mephedrone, died in hospital 3 weeks later from acute liver failure – 1 
Attended party where took mephedrone and heroin, collapsed died in hospital 3 weeks 
later – 1 
Died in hospital after taking mephedrone – 1 
Indulged in sexual activity, self-injected mephedrone, had seizure and collapsed – 1 
Had taken large amounts of methcathinones, engaged in auto-erotic asphyxiation with 
plastic bag over head, but accidentally suffocated - 1  
Consumed amphetamine & mephedrone, vomited, felt cold & sleepy; taken to hospital 
where, despite treatment, suffered liver problems & multi-organ failure – 1 
Found unresponsive in bed, death certified at scene; had been feeling unwell, on 
medication for chronic abdominal & back pain – 1 
Admitted to Emergency Department previous day with drug overdose, had been partying 
but later found hanging – 1 
Aspirated blood following mixed drug (including mephedrone) intoxication - 1 
Had consumed GHB and mephedrone; found dead beside bed at home by a friend – 1 
Not known – 2 
Table 3. Events leading to death 
 
1a Hanging – 10 
1a Hanging; 2 Mephedrone withdrawal – 1 
1a Hanging; 2 alcohol and mephedrone use – 1 
1a Hanging; 2 using mephedrone - 1 
1a Shotgun wound to head; 2 Use of mephedrone, methylone and cocaine – 1 
1a Blood loss following fatal stabbing to thigh [inflicted by third party] – 1 
1a Exsanguination; 1b Neck laceration cutting left jugular vein [self-inflicted] – 1 
1a Multiple injuries; 1b Blunt force trauma; 1c Vehicular collision (driver) – 1 
1a Ruptured inferior vena cava with haemorrhage in abdominal cavity & cervical spine 
fracture; 1b Road traffic accident; 2 Cirrhosis of liver & misuse of drugs – 1 
1a Multiple injuries [road traffic accident] – 1 
1a Multiple injuries [fall from height] – 1 
1a Drowning; 2 Multiple drug overdose – 1 
1a Hypothermia; 1b Drug overdose [quetiapine, lorazepam, venlafaxine, mephedrone] - 1 
1a Adverse effects of mephedrone - 1 
1a Poisoning by mephedrone – 1 
1a Mephedrone toxicity - 1 
1a Mephedrone poisoning; 2 Coronary artery disease – 1 
1a Adverse effects of mephedrone; 2 Atherosclerotic coronary artery disease; myocardial 
fibrosis – 1 
1a Mephedrone intoxication – 2 
1a Cardiac arrest following ingestion of mephedrone – 1 
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1a Seizure; 1b Effect of mephedrone – 1 
1a Cardiac arrest, cause unascertained between multiple drug toxicity [mephedrone, 
MDPV, fluoromethcathinone] and/or Excited Delirium – 1 
1a Aspiration of blood; 1b Mixed drug intoxication [inc. mephedrone] - 1 
1a Adverse effects of methadone and mephedrone – 1 
1a Overdosage of mephedrone (meow meow) compounded by cocaine; 2 Cocaine abuse - 1 
1a Mixed MDMA and mephedrone toxicity – 1 
1a Combined toxic effects of amphetamine and mephedrone – 1 
1a Patchy bronchopneumonia & pulmonary oedema; 1b Cardiac ischaemia, contributed to 
by mephedrone, citalopram and diazepam - 1 
1a Ischaemic heart disease; 1b Illicit use of cathinones - 1 
1a Toxic effects of drugs [inc. mephedrone] – 1 
1a Fatal drug intoxication [inc. mephedrone] – 1 
1a Mixed drug toxicity [inc. mephedrone] – 1 
1a Hypoxic brain injury; 1b Mixed drug overdose [inc. mephedrone] - 1 
1a Hypoxic brain injury; 1b Cerebral oedema; 1c Ingestion of psychoactive drug [inc. 
mephedrone] – 1 
1a Toxic effects of alcohol and cocaine – 1 
1a Heroin and alcohol toxicity - 1 
1a GHB intoxication – 2 
1a Acute alcohol poisoning – 1 
1a Morphine (heroin) toxicity - 1 
1a Morphine toxicity (on balance of probability) – 1 
1a BZP and TFMPP toxicity – 1 
1a Illicit methadone misuse – 1 
1a Combined effects of alcohol and GBL intoxication – 1 
1a Combined toxic effects of alcohol, dihydrocodeine and atropine/hyoscine (from Datura 
Stramonium) together with postural asphyxia - 1 
1a Systemic sepsis, resulting in cardiac arrest; 1b Bronchopneumonia; 1c Beta haemolytic 
Streptococcal Group A infection – 1 
1a Medication toxicity; 2 Acute & chronic debilitating back pain, early stage 
bronchopneumonia - 1 
1a Combined methadone and alcohol overdose – 1 
1a Amitriptyline/Methadone overdose - 1 
1a Asphyxia [plastic bag suffocation] – 1 
(Where cause of death sections of the death certificate specifically mentioned mephedrone 
or where it was included in verdict. Mephedrone was implicated on its own in 18 cases, 
with other substances in 18 cases. In many of the hanging causes, mephedrone was 
considered to have played a contributory role although not recorded in the cause of death.) 
Table 4. Cause of deaths associated with mephedrone reported to np-SAD 
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10.4 Drugs implicated 
Mephedrone was specifically mentioned as being present at post-mortem in 59 cases. The 
drug was formally included in the cause of death in 18 cases and implicitly (e.g. polydrug 
toxicity given in the cause of death without specifying particular drugs, but mephedrone 
was found in post-mortem analysis or mentioned by the pathologist as contributing to 
death) in 10 further cases. In a further case, the drug was not mentioned either as being 
present at post-mortem (death occurred 3 weeks after mephedrone consumption) or in the 
cause of death although stated by witnesses to have been consumed.  
Where details of the drugs present at post-mortem (or ante-mortem) were given, mephedrone 
alone was used on eight occasions, solely with alcohol in four cases, and in combination with 
further substances in 18 cases (Table 5). In 15 cases mephedrone was ingested with stimulants, 
and with diazepam in 13 cases. It is noteworthy that other newly emerging psychoactive 
substances were also here identified, including: GBL/GHB, ketamine, and piperazines, as well 
as other methcathinones (n = 8), especially MDPV. Prescribed medications were also present: 
opioids including methadone; hypnotics/sedatives; antidepressants; antipsychotics; and 
antiepileptics.  
 
(Mephedrone was present in 59 cases, including 2 ante-mortem. It had been consumed in 
all cases in the period leading up the incident causing death.) 
 
Mephedrone sole mention – 8 
Mephedrone with alcohol – 4 
Mephedrone and alcohol and other drugs  -  18 
Mephedrone with cannabis – 4 
Mephedrone with stimulants – 15 
Mephedrone with diazepam - 13 
Mephedrone with opiates – 12 
Mephedrone with piperazines – 7 
Mephedrone with GBL/GHB – 5 
Mephedrone with ketamine – 2 
Mephedrone with other methcathinones – 8 
Mephedrone with antidepressants – 5 
Mephedrone with antipsychotics - 2 
Mephedrone with antiepileptics - 1 
Mephedrone with hypnotics/sedatives (exc. Diazepam) – 3 
Table 5. Summary of drug combinations and positive toxicological findings for deaths 
associated with mephedrone reported to np-SAD 
10.5 Toxicology 
Full details of mephedrone levels are given in Table 6; actual levels were quantified in 36 cases 
(Table 6). Overall: (n = 36) mean = 1.586mg/l, range = <0.01 – 22.0mg/l; mono-mephedrone 
cases (n = 10) mean = 1.996mg/l range = <0.01 – 12.15mg/l; combined mephedrone cases (n = 
26): mean = 1.429mg/l; range = 0.03 – 22.0mg/l. These figures exclude one combined 
mephedrone case with a level of >2000mg/l. 
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Case  
No.  
Mephedrone 
present 
Mephedrone 
levels  
Second drug 
present 
Third drug 
present 
Fourth drug 
present 
Fifth drug 
present 
Sixth drug 
present 
1 Yes bl 0.04mg/l methadone diazepam olanzapine chlorproma-
zine 
 
2 Yes bl <0.01mg/l 
ur + 
     
3 Yes bl 0.76mg/l alcohol GBL diazepam & 
metabolites 
  
4 Yes bl 1.3mg/l 
ur + 
     
5 Yes bl 0.07mg/l, 
0.15mg/l ur 
16mg/l 
alcohol diazepam    
6 Yes bl 0.41mg/l, 
0.42mg/l 
diazepam citalopram    
7 Yes bl + alcohol cocaine & 
metabolite 
lignocaine   
8 Yes bl 16ug/l alcohol     
9 Yes bl detected alcohol cocaine cocaethylene levamisole lignocaine 
10 Yes bl 2.1ug/ml alcohol     
11 Yes bl 0.21ug/ml 
ur + 
GBL TFMPP ketamine methylamph
etamine 
diazepam 
12 Yes bl 2.24mg/l, 
ur + 
TFMPP alcohol    
13 Yes bl 1.0mg/l MDMA     
14 Yes bl 0.32mg/l      
15 Yes bl 0.88mg/l , 
ur +, 
stomach + 
paracetamol     
16 Yes bl 22mg/l alcohol amphetamine diazepam   
17 Yes bl 0.04mg/l, 
0.19mg/l, ur 
64.8mg/l, 
stomach 
2.65mg/l 
     
18 Yes bl 
0.108mg/l, 
0.08mg/l 
alcohol diazepam    
19 Yes bl 3.3mg/l, 
stomach +, 
hair 
4.2ng/mg, 
4.7ng/mg 
     
20 Yes bl > 
2.0mg/ml 
ampheta-
mine 
BZP TFMPP  chlorpheni-
ramine 
 
21 Yes bl 9.01ug/ml, 
ur 
0.01ug/ml, 
stomach + 
morphine cannabis    
 
Pharmacology 
 
370 
Case  
No.  
Mephedrone 
present 
Mephedrone 
levels  
Second drug 
present 
Third drug 
present 
Fourth drug 
present 
Fifth drug 
present 
Sixth drug 
present 
22 No - morphine     
23 Yes AM serum 
0.042mg/l, 
ur + 
     
24 Yes bl 
12.15mg/l, 
ur + 
     
25 Yes ur + cocaine methylone    
26 Yes ur + alcohol pyrovalerone BZP FTMPP  
27 Yes bl 0.31ug/ml cannabis     
28 Yes bl trace morphine quetiapine    
29 Yes bl 0.07mg/l alcohol     
30 Yes bl + alcohol BZP TFMPP paracetamol citalopram 
31 Yes bl + alcohol paracetamol citalopram zopiclone  
32 Yes AM bl +      
33 Yes bl 0.08ug/ml methylone MDPV GBL   
34 Yes bl + methadone alcohol cocaine   
35 Yes bl + recent 
use 
alcohol benzocaine    
36 Yes bl + recent 
use 
alcohol benzocaine    
37 Yes bl 0.03ug/ml cannabis     
38 Yes bl + ur + diazepam     
39 Yes bl low level diazepam cannabis    
40 Yes bl + ampheta-
mine 
    
41 Yes ur + alcohol cocaine & 
metabolites 
   
42 Yes bl 6.2mg/l diazepam & 
metabolites 
gabapentin oxycodone   
43 Yes bl + alcohol cannabis diazepam   
44 Yes bl 0.05mg/l GHB alcohol ampheta-
mine 
cocaine & 
metabolites 
methadon
e 
45 Yes bl 
0.033ug/ml, 
bile 
0.05ug/ml, 
ur 
0.24ug/ml 
     
46 Yes bl 1.7mg/l  BZP TFMPP codeine diazepam  
47 Yes bl <0.05mg/l, 
ur 11.67mg/l
alcohol venlafaxine quetiapine halperidol lorazepam 
48 Yes bl 0.51mg/l alcohol     
49 Yes bl <0.3125, 
ur + 
alcohol MDPV cocaine levamisole quinine 
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Case  
No.  
Mephedrone 
present 
Mephedrone 
levels  
Second drug 
present 
Third drug 
present 
Fourth drug 
present 
Fifth drug 
present 
Sixth drug 
present 
50 Yes bl 0.17mg/l MDPV MDMA MDA cocaine diazepam 
51 Yes ur + methylam-
phetamine
amphetamine GHB ketamine  
52 Yes n/k alcohol morphine cocaine fluoxetine  
53 Yes bl 0.04mg/l, 
ur +
alcohol dihydroco-
deine
atropine hyoscine 
butylbromide 
diazepam 
54 Yes bl 
<0.005mg/l
morphine nitrazepam buprenor-
phine
mirtazapine  
55 Yes bl 0.21mg/l cocaine levamisole alcohol  
56 Yes n/k methadone amitriptyline nitrazepam  
57 Yes ur 
<0.005mg/l
flephedrone MDPV ibuprofen unidentified 
compounds 
 
58 Yes n/k MDPV MDPBP pentylone cocaine 
metabolites 
 
59 Yes bl 0.05mg/l, 
ur 0.05mg/l
MDPV fluoromethcat
hinone
diazepam  
60 Yes bl 1.94mg/l BZP TFMPP diazepam  
Table 6. Combinations of post mortem drugs in deaths associated with mephedrone (levels) 
reported to np-SAD 
11. Discussion 
The existence of the Special Mortality Register maintained by the National Programme on 
Substance Abuse Deaths fulfills several major roles: it provides a unique UK-wide historic 
repository of unparalleled detailed information on drug-related deaths and deaths of drug 
addicts since 1997; the provision of a nation-wide surveillance capability for monitoring 
substance-related deaths; and the provision of information on the epidemiology of such events. 
This paper contributes to the knowledge-base on mephedrone by providing 
supplementary/complementary information on the epidemiology of its use in the UK 
through the provision of centralised collation of post mortem toxicological results. 
Furthermore, this report has provided an analysis of the only UK-wide, mephedrone-
specific mortality dataset. Although not all cases have yet been fully investigated, to the best 
of our knowledge this is the most comprehensive and detailed study of deaths associated 
with mephedrone in the literature.  
11.1 User profile 
One in five of ‘mephedrone fatalities’ turned out here not to be actually related to 
mephedrone, since the drug was actually not identified at post mortem. This might be 
understood in the context of the high levels of both media attention and public concerns 
surrounding the unprecedented rapidity of the appearance of mephedrone in the UK 
recreational drug market (Davey et al., 2010). However, some of these cases turned out to 
involve other methcathinones such as MDPV. 
Typical mephedrone victims in this study were young (78% under 35 years of age); male 
(75%); White (96% where ethnicity was known); either in full time employment, 
 
Pharmacology 
 
372 
unemployed or students; and with a previous history of drug misuse (73% where known). 
With an average age of 29 years and nearly four-fifths under the age of 35, the age profile of 
this dataset is much younger than cases typically reported to np-SAD (Ghodse et al., 2010).  
Mephedrone misuse in the UK is likely to have started as early as 2007 (Davey et al., 2010), 
and the first mephedrone-related fatality recorded on the np-SAD database occurred in 
September 2009. Although further studies are needed to confirm present observations, it 
seems from the information presented here that reports of mephedrone fatalities dropped in 
the months following the announcement by the Home Office on 30 March 2010 that the 
chemical, together with other related substances, was going to become a Controlled Drug. 
However, there was a further peak in July 2010, as well as additional deaths occurring in 
February, April and May 2011. This suggests that mephedrone, as well as other illegal 
methcathinones, are still being consumed in the UK.  
The excess number (doubling) of observed mephedrone-associated fatalities between 
Saturdays and Tuesdays, compared to other days of the week, might be explained by its 
more frequent intake over the weekend, confirming once again its recreational drug profile. 
An issue of particular concern and, to the best of our knowledge, something previously 
unreported is that 16 victims (about 1 in 3 cases of the current sample) either hanged 
themselves (13 cases), or used particularly violent means to terminate their own lives. In 10 
cases, the coroner gave a verdict of suicide and in 8 further cases an open verdict was returned. 
In most of these cases, mephedrone was considered to have played a contributory role. 
Although a full psychiatric history is not typically made available to np-SAD, it is worth 
emphasizing that, out of the whole sample, antipsychotics were here identified at post mortem 
in 2 cases and antidepressants in 5 cases. Therefore, it can be postulated that mephedrone 
(either on its own, or in a polydrug misuse combination) has the potential to cause and/or 
exacerbate psychosis and/or depression, thus facilitating the occurrence of bizarre 
behaviour/self harm with particularly violent means. In one instance, the possibility of Excited 
Delirium was recorded. Although the present report comments on only 60 cases, the suicide 
rates in our other UK studies of stimulant-related fatalities were quantitatively less significant, 
being in the range of 3-6%: amphetamine-type drugs (Schifano et al., 2010); MDMA/ecstasy 
(Schifano et al., 2010; Schifano et al., 2003b); cocaine (Schifano & Corkery, 2008). The rate for 
khat-related fatalities was about 31% (sample size = 13) (Corkery et al., 2010).   
Contributory clinical (e.g. sepsis; bronchopneumonia; pre-existing atherosclerotic 
cardiovascular conditions) and environmental (e.g. involvement in traffic accidents, 
drowning, hypothermia) factors were here identified at post mortem in respectively 5 and 5 
mephedrone fatalities. These observations are overall consistent with the existing literature 
on stimulant misuse and may reflect the sympathomimetic actions of mephedrone and the 
accident-proneness or risk-taking behaviour of stimulant, including mephedrone, misusers 
(Schifano et al., 2011).  
Mean mephedrone blood levels at post mortem were of either about 1.43mg/l (in polydrug 
cases) or 2.00mg/l (mono-intoxication fatalities), which is broadly in line with previous, 
small scale, anecdotal observations (Dickson et al., 2010; Lusthof et al., 2011). 
11.2 Mephedrone use with other substances 
Although mephedrone was here identified on its own in the cause of death in only one-third 
of cases (n = 18, 30%), this finding confirms some of the concerns recently expressed 
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regarding the acute toxicity potential of the drug itself (James et al., 2011; Maskell et al., 
2011; Schifano et al., 2011; Torrance & Cooper, 2010; Wood et al., 2010; Regan et al., 2010). It 
could be argued that the fact there are such a relatively large number of deaths in a 
comparatively short period (two years) underlines the need to inform consumers of its 
potential to cause death on its own. 
Conversely, most mephedrone victims died of polydrug, and especially alcohol, 
consumption. Anecdotally, it appears that alcohol is taken in association with stimulants to 
get a stronger/better ‘high’. Similarly, other stimulants such as MDMA/ecstasy, whilst in 
the presence of alcohol, show more significant physiopathological effects (Pacifici et al., 
2002; Schifano et al., 2003a). In 15 cases mephedrone was ingested with stimulants.  Cocaine, 
amphetamines, other methcathinones and/or ecstasy tablets may be taken to maintain 
arousal and a state of alertness, since the stimulant desired effects of mephedrone fade away 
in a few hours (Schifano et al., 2011). However, co-ingestion of two stimulants could 
increase, in a synergic way, both the dopaminergic and serotonergic stimulation, and this is 
likely to increase mephedrone toxicity effects and harm potential (Schifano et al., 2011). In 
other cases, arguably to modulate its stimulant effects, mephedrone was associated in this 
study with opiates (12 cases) and/or diazepam (13 cases). This is likely to be consistent with 
the observation made here that, where known, about 3 out of 4 victims had a history of drug 
misuse. It is noteworthy that other newly emerging psychoactive substances (including: 
GBL/GHB, ketamine, piperazines, as well as other methcathinones) were also found in 
several cases in conjunction with mephedrone; this is in line with the literature (Deluca et 
al., 2009; Schifano et al., 2011). In all of these polydrug abuse cases, the precise role of 
mephedrone in causing fatality was due to simultaneous drug use and remains unclear. 
Conversely, the use of stimulants might afford some protective effects to those who 
overdosed with sedatives.  
11.3 Treatment and prevention of fatalities 
The patterns of drug use evidenced by post mortem toxicology results are similar to those 
reported by surveys and online users’ fora; polysubstance use is common, especially the co-
ingestion of alcohol, stimulants and other ‘legal highs’. The pathologies (including 
psychopathologies) exhibited in many of these cases exhibit close similarities to those 
previous noted for amphetamine, cocaine, MDMA and khat. The implication of these 
findings is that similar advice to that already given for adverse events caused by other 
stimulants should be provided to clinicians, the emergency services and first-aiders. It is 
suggested that the treatment for more life-threatening conditions might be broadly similar 
to that for amphetamine poisoning. Individuals with less severe symptoms should be 
assessed and managed as for any psychoactive drug user; they may simply need 
reassurance, support and observation. People with underlying cardiac, neurological and 
psychiatric conditions, especially those on medication, are likely to be at greatest risk of 
serious adverse events (Winstock et al., 2010). 
Although our knowledge of mephedrone’s potential neurotoxicity or long-term 
consequences of its use is still very limited, it is sensible to offer the following advice: 
avoiding regular use to avoid developing tolerance; not using the drug in combination with 
other stimulants or large amounts of alcohol and other depressants; not injecting the drug; 
remaining well hydrated when using the drug; and avoiding becoming overheated. Brief 
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motivational interventions and appropriately adapted psychosocial intervention may be 
employed to treat mephedrone addiction (Winstock et al., 2010). 
11.4 Limitations  
A number of limitations need to be borne in mind in respect of this study: (a) not all 
suspected cases may have been identified; (b) remaining 'positive' cases are awaiting further 
inquiries or inquest; (c) the fact that mephedrone may have been involved in death cannot 
be confirmed until the relevant Coroner or Procurator Fiscal has concluded her/his inquest 
or other formal inquiry; (d) the presence of mephedrone in post mortem toxicology does not 
necessarily imply that it caused or contributed to a death; (e) not all completed cases have 
been formally notified to the Programme for recording. Hence, the number of identified 
cases reported here is likely to be an underestimation. 
It is thought unlikely that the changes in fatality rates over time observed here are related to 
parallel changes in coroner methods, which would in turn affect surveillance. Data 
collection methods have remained unchanged. However, greater awareness of the 
phenomenon, improved case identification methods, and the devopment of new approaches 
in forensic toxicology and the range of substances now routinely screened for may have led 
to more potential cases being notified and registered.  
Further limitations of the present report may include: lack of analytical attention to the role 
of the possible triggering environmental factors (i.e. overcrowding; hot settings etc); lack of 
total geographical coverage of coroner’s jurisdictions; possible incomplete information 
relating to the prescription of psychoactive medications; and lack of information for some 
fatalities on the concentration of mephedrone detected in body fluids, so that some victims 
might have had only traces of the substance. Finally, since mortality rates (e.g. number of 
deaths out of number of mephedrone intake occasions) were not here calculated, it may be 
difficult to determine the true extent of risks associated with mephedrone consumption. 
However, in at least one case death occurred on the first use of mephedrone (albeit in 
combination with amphetamine). 
12. Conclusions 
This chapter has highlighted the dangers associated with mephedrone consumption, 
especially with regard to recreational use. This study represents the most detailed analysis 
to date of the largest number of mephedrone-related fatalities world-wide. It is hoped that it 
will thereby make a major contribution to the evidence-base being built up on this drug, and 
therefore, to reducing drug-related deaths.      
Although identified on its own in only a minority of cases, present data confirm concerns 
regarding the acute toxicity potential of the drug. It is of concern that about 1 in 3 cases of 
the current sample used particularly violent means to terminate their own lives.  
The number of mephedrone intake occasions was not calculated here, and so it may be 
difficult to determine the true extent of risks associated with mephedrone consumption. It 
may be possible to compare the lethality of mephedrone with other substances building on 
methods developed by King and Corkery (2010).  
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Further studies of a similar nature should be conducted in other countries, to see if the 
clinical and toxicity patterns associated with mephedrone use described here are confirmed. 
Notwithstanding the possible biases outlined above, the number of cases reported here may 
however suggest a significant level of caution when ingesting mephedrone for recreational 
purposes. 
The limited information yet available on mephedrone underlines the need for basic  pre-
clinical and in-vitro research (and the necessary funding to carry it out) on the 
pharmacology, metabolism, etc. of methcathinones so as to provide evidence-based 
interventions and treatments. 
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